Rain Therapeutics

Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company was founded by Avanish Vellanki and Robert Doebele in April 2017 and is headquartered in Newark, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rain Oncology is a clinical-stage company focusing on research and development of innovative therapies for cancer patients.  Rain Oncology provides a tumor-agnostic strategy to select patients based on tumors’ underlying genetics rather than histology.  Rain Oncology was founded in 2017 and was headquartered in Newark, California.

Shares have fallen by nearly 40% since 2021 IPO. Oral MDM2 inhibitor milademetan potentially has an efficient path to market via pivotal study in WD/DD LPS (rare cancer).

Rain Oncology: Multiple Data Catalysts In 2023 For This Precision Oncology Pioneer

NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Rain Oncology (NASDAQ: RAIN), the company is updating their presentation date and time to Thursday, February 9, 2023, at 3:55 p.m. ET.

UPDATE – Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference

NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be participating in a fireside chat at the Guggenheim Healthcare Talks Oncology Day Conference on Wednesday, February 8, 2023, at 9:35 a.m. ET, being held in New York, NY.

Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference

– Intermittent dosing of milademetan, an inhibitor of the p53-MDM2 complex, potentially exhibits an avenue to address historical issues with cytopenias with this class of compounds–

Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology

Aziyo Biologics, Inc

Cadiz

Cognition Therapeutics

 Clene Nanomedicine

Eterna Therapeutics Inc

HireRight GIS Group Holdings LLC

Dave & Buster's

Tenaya Therapeutic

The Fintel Insider Sentiment quant model identifies US stocks that have experienced significant insider buying activity over the last 90 days.

These 10 Stocks Had the Most Insider Buying Activity During the December Quarter

NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will change its name to Rain Oncology Inc. effective tomorrow, December 30, 2022, to better reflect the company's focus on addressing unmet needs for cancer patients through precision oncology.

Rain Therapeutics Inc. Announces Name Change to Rain Oncology Inc.

NEWARK, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will be participating in J.P. Morgan's 41st Annual Health Care Conference, being held January 9 – 12, 2023, in San Francisco, CA.

Rain Therapeutics to Participate in the 41st Annual J.P. Morgan Health Care Conference

NEWARK, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the upcoming 2022 San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, 2022 in San Antonio, TX.

Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

NEWARK, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will be participating in Piper Sandler's 34th Annual Healthcare Conference, being held November 29 – December 1, 2022, in New York.

Rain Therapeutics to Participate in Piper Sandler's 34th Annual Healthcare Conference

NEWARK, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an oral presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place on November 16-19, 2022 in Vancouver, BC, Canada.

Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting

NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in H.C. Wainwright's 3rd Annual Precision Oncology Conference on November 14, 2022.

Rain Therapeutics to Participate in H.C. Wainwright's 3rd Annual Precision Oncology Virtual Conference

Rain Therapeutics Inc. (NASDAQ:RAIN ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Dan Ferry – LifeSci Advisors Avanish Vellanki – Chief Executive Officer Robert Doebele – Chief Scientific Officer Richard Bryce – Chief Medical Officer Nelson Cabatuan – Senior Vice President-Finance Conference Call Participants Michael Schmidt – Guggenheim Yigal Nochomovitz – Citi Jeff Jones – Oppenheimer Mitchell Kapoor – H.C. Wainwright Soumit Roy – Jones Research Operator Greetings, and welcome to the Rain Therapeutics Third Quarter Earnings Conference Call.

Rain Therapeutics Inc. (RAIN) Q3 2022 Earnings Call Transcript

– End of third quarter cash position of $90.7 million excludes the recent $50 million registered offering, and together, provide a cash runway into 2025 –

Rain Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting common stock. The shares are being sold at an offering price of $5.83 per share, which is priced at the closing price on Nasdaq for Rain's common stock on November 3, 2022. The shares of non-voting common stock are convertible into an equal number of shares of common stock, subject to beneficial ownership limitations. The gross proceeds to Rain, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $50 million. The offering is expected to close on or about November 8, 2022, subject to customary closing conditions. Rain has granted the underwriters a 30-day overallotment option to purchase up to 1,286,449 additional shares of common stock at the offering price, less underwriting discounts and commissions.

Rain Therapeutics Announces $50 Million Registered Offering of Common Stock

- Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression activity out of ten efficacy evaluable patients, demonstrating monotherapy activity of milademetan in MDM2-amplified patients -

Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)

NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results.

Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022

NEWARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the 34th EORTC/AACR/NCI Symposium taking place on October 26-28, 2022 in Barcelona, Spain.

Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium

NEWARK, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in Citi's 17th Annual BioPharma Conference on September 7-8, 2022 taking place at the Four Seasons Hotel in Boston, MA.

Rain Therapeutics to Participate in Citi's 17th Annual BioPharma Conference

Rain Therapeutics Inc. (NASDAQ:RAIN ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Bob Yedid – LifeSci Advisors Avanish Vellanki – Chief Executive Officer Nelson Cabatuan – Senior Vice President of Finance Bob Deobele – President and Chief Scientific Officer Richard Bryce – Chief Medical Officer Conference Call Participants Yige Guo – Guggenheim Sam Kurtz – Piper Sandler Jeff Jones – Oppenheimer Soumit Roy – Jones Research Tony Butler – ROTH Capital Operator Good day, and welcome to the Rain Therapeutics Second Quarter 2022 Earnings Conference Call. Today's conference is being recorded.

Rain Therapeutics Inc.'s (RAIN) CEO Avanish Vellanki on Q2 2022 Results - Earnings Call Transcript

– Quarter-end cash position of $105.7 million provides ample cash runway into mid-2024 –

Rain Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance –

UPDATE -- Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma

Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma

NEWARK, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the second quarter ended June 30, 2022 and highlights of recent progress on Thursday, August 4, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results.

Rain Therapeutics to Report Second Quarter 2022 Financial Results and Highlights of Recent Progress on August 4, 2022

Rain Therapeutics Inc. (NASDAQ:RAIN ) Q1 2022 Results Conference Call May 4, 2022 5:00 PM ET Company Participants Bob Yedid - LifeSci Advisors Avanish Vellanki - CEO Robert Doebele - Chief Scientific Officer Richard Bryce - Chief Medical Officer Nelson Cabatuan - SVP, Finance Conference Call Participants Corinne Jenkins - Goldman Sachs Soumit Roy - Jones Trading Carly Kenselaar - Citi Yige Guo - Guggenheim Securities Operator Good afternoon, and welcome to the Rain Therapeutics First Quarter 2022 Earnings Call. [Operator Instructions] Please note this event is being recorded.

Rain Therapeutics Inc. (RAIN) CEO Avanish Vellanki on Q1 2022 Results - Earnings Call Transcript

– Quarter-end cash position of $123.2 million provides ample cash runway into first half of 2024 –

News for Rain Therapeutics Stock (RAIN)